首页> 外文期刊>Journal of cardiac failure >Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
【24h】

Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.

机译:阿托伐他汀调节慢性心力衰竭患者的Th1 / Th2反应。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The T-helper (Th)1/Th2 imbalance has been demonstrated to be involved in chronic heart failure (CHF). We sought to determine whether atorvastatin exhibited any effect on CHF through modulating the Th1/Th2 response. METHODS AND RESULTS: We measured serum concentrations of interleukin (IL)-12, -18, interferon (IFN)-gamma, IL-4, and IL-10 from 20 controls and 72 patients with nonischemic CHF by enzyme-linked immunosorbent assay. To investigate the effect of atorvastatin in vivo, CHF patients were either classified into a usual therapy group (n = 35) or usual therapy plus atorvastatin (10 mg/day) group (n = 37). Patient serum levels of IFN-gamma and IL-4 were measured at time of admission and 2 weeks after treatment. Peripheral blood mononuclear cells from patients of CHF group were cultured in the presence or absence of atorvastatin (0, 0.4, 1, and 4 micromol/L) in vitro, and IFN-gamma and IL-4 levels were detected. Serum levels of IL-12, IL-18, and IFN-gamma were significantly higher in the CHF group than in the control group. The levels of IFN-gamma and the ratios of IFN-gamma:IL-4 were significantly decreased with atorvastatin treatment both in vivo and in vitro, whereas levels of IL-4 did not differ significantly. CONCLUSIONS: Th1 polarization exists in patients with CHF, and atorvastatin can modulate the Th1/Th2 response through inhibiting Th1 cytokine production.
机译:背景:已证明T辅助(Th)1 / Th2不平衡与慢性心力衰竭(CHF)有关。我们试图确定阿托伐他汀是否通过调节Th1 / Th2反应对CHF产生任何影响。方法和结果:我们通过酶联免疫吸附测定法从20名对照和72名非缺血性CHF患者中测量了白细胞介素(IL)-12,-18,干扰素(IFN)-γ,IL-4和IL-10的血清浓度。为了研究阿托伐他汀在体内的作用,将CHF患者分为常规治疗组(n = 35)或常规治疗加阿托伐他汀(10 mg /天)组(n = 37)。在入院时和治疗后2周测量患者的IFN-γ和IL-4血清水平。在有或没有阿托伐他汀(0、0.4、1和4 micromol / L)存在的情况下,对CHF组患者的外周血单个核细胞进行培养,并检测IFN-γ和IL-4水平。 CHF组的血清IL-12,IL-18和IFN-γ水平显着高于对照组。阿托伐他汀治疗在体内和体外均显着降低了IFN-γ的水平和IFN-γ:IL-4的比率,而IL-4的水平没有显着差异。结论:CHF患者存在Th1极化,阿托伐他汀可以通过抑制Th1细胞因子的产生来调节Th1 / Th2反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号